Ranbaxy Pharmaceuticals Canada Inc., a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received approval in Canada to manufacture and market Ran-Simvastatin 5 mg, 10 mg, 20 mg, 40 mg and 80 mg tablets (Simvastatin) from Health Canada, Therapeutic Products Directorate (TPD).
The details can be read here.
No comments:
Post a Comment